Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection

Next Previous
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 101 Arbutus Biopharma (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arbutus Biopharma

Most Recent Events

  • 14 May 2025 According to an Arbutus Biopharma media release, company presented safety, tolerability and evidence of high receptor occupancy data in eleven of the thirteen evaluable healthy subjects that received either single or multiple doses of 40mg of AB-101.
  • 14 May 2025 Results presented in an Arbutus Biopharma media release
  • 07 May 2025 According to an Arbutus Biopharma media release, part 3 data presented at the European Association for the Study of the Liver (EASL) Congress 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top